Ablatus Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Liquidation

Ablatus Therapeutics General Information

Description

Developer of medical devices designed to use ablation technology to treat solid tumors. The company's proprietary technology generates radiofrequency (RF) energy, which when delivered to target tissues via probe results in localized heating and tissue destruction, enabling doctors to have clinical options for treatment and improve patient outcomes.

Contact Information

Website
www.ablatus.co.uk
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Saint Johns Innovation Centre
  • Cowley Road
  • Cambridge CB4 0WS
  • England, United Kingdom
Primary Industry
Surgical Devices
Other Industries
Other Devices and Supplies
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Saint Johns Innovation Centre
  • Cowley Road
  • Cambridge CB4 0WS
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ablatus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Bankruptcy: Liquidation 01-Oct-2024 Completed Bankruptcy: Liquidation
10. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
9. Later Stage VC 16-May-2024 Completed Generating Revenue
8. Later Stage VC (Series A) 28-Jun-2021 Completed Generating Revenue
7. Grant 25-Aug-2020 Completed Generating Revenue
6. Early Stage VC 19-Apr-2018 Completed Startup
5. Grant 01-Sep-2017 Completed Startup
4. Seed Round 11-Jul-2016 Completed Startup
3. Accelerator/Incubator $170K $170K Completed Startup
2. Accelerator/Incubator 01-Jan-2015 Completed Startup
To view Ablatus Therapeutics’s complete valuation and funding history, request access »

Ablatus Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
B Ordinary
A Ordinary 1,144,067 $0.000012 $1.61 $1.61 1x $1.61 31.98%
Ordinary 495,000 $0.000012 $1.25 $1.25 1x $1.25 13.84%
To view Ablatus Therapeutics’s complete cap table history, request access »

Ablatus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medical devices designed to use ablation technology to treat solid tumors. The company's proprietary techno
Surgical Devices
Cambridge, United Kingdom
4 As of 2024

Mason, OH
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ablatus Therapeutics Competitors (18)

One of Ablatus Therapeutics’s 18 competitors is Atricure, a Formerly VC-backed company based in Mason, OH.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Atricure Formerly VC-backed Mason, OH
CivaTech Oncology Venture Capital-Backed Durham, NC
NorthStar Medical Radioisotopes Venture Capital-Backed Beloit, WI
OptMed Formerly VC-backed New York, NY
REVA Medical Formerly VC-backed San Diego, CA
You’re viewing 5 of 18 competitors. Get the full list »

Ablatus Therapeutics Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Ablatus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201907269-D0 Conductive member for use in radiofrequency ablation Active 23-May-2019
EP-3972507-A1 Conductive member for use in radiofrequency ablation Inactive 23-May-2019
GB-2584278-A Conductive member for use in radiofrequency ablation Active 23-May-2019
US-20220218983-A1 Conductive member for use in radiofrequency ablation Inactive 23-May-2019
GB-2584278-B Conductive member for use in radiofrequency ablation Active 23-May-2019 A61B18/1477
To view Ablatus Therapeutics’s complete patent history, request access »

Ablatus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Ablatus Therapeutics FAQs

  • When was Ablatus Therapeutics founded?

    Ablatus Therapeutics was founded in 2015.

  • Where is Ablatus Therapeutics headquartered?

    Ablatus Therapeutics is headquartered in Cambridge, United Kingdom.

  • What is the size of Ablatus Therapeutics?

    Ablatus Therapeutics has 4 total employees.

  • What industry is Ablatus Therapeutics in?

    Ablatus Therapeutics’s primary industry is Surgical Devices.

  • Is Ablatus Therapeutics a private or public company?

    Ablatus Therapeutics is a Private company.

  • What is Ablatus Therapeutics’s current revenue?

    The current revenue for Ablatus Therapeutics is .

  • How much funding has Ablatus Therapeutics raised over time?

    Ablatus Therapeutics has raised $7.22M.

  • Who are Ablatus Therapeutics’s competitors?

    Atricure, CivaTech Oncology, NorthStar Medical Radioisotopes, OptMed, and REVA Medical are some of the 18 competitors of Ablatus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »